Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 17, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons in the company's Ordinary Shares, specifically relating to the GlaxoSmithKline Employee Trust (GSK Trust).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of share transactions rather than a financial performance report.
Material Changes
The filing details specific share movements within the GSK Trust during mid-October 2005:
- October 14, 2005: The GSK Trust transferred 19,598 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- October 14, 2005: The GSK Trust sold 4,636 Ordinary Shares at GBP 14.52 per share on behalf of participants in the GlaxoSmithKline Restricted Share Plan.
- October 17, 2005: The GSK Trust transferred 14,668 Ordinary Shares to participants in the GlaxoSmithKline Restricted Share Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold interests in the shares held by the GSK Trust in the same capacity as other employees. The transactions were notified in accordance with Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the total number of shares transferred to employee plans (34,266 shares) versus shares sold (4,636 shares) during the reporting week.
- Confirm the sale price of GBP 14.52 per share against the market price on October 14, 2005.
- Review the specific terms of the SmithKline Beecham Employee Share Option Plan 1991 and the GlaxoSmithKline Restricted Share Plan to understand vesting conditions.
- Check subsequent filings for any additional director-related transactions or changes in the GSK Trust holdings.